Marianne Leheurteur - Concepedia

Author

Marianne Leheurteur

Centre Jean Perrin

Also Known As

Anthony Gonçalves, Leheurteur, Marianne, M Leheurteur, M. Leheurteur, Marianne LeHeurteur, Marianne Leheurteur

176

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Centre Jean Perrin Inserm Centre Léon Bérard Centre Henri Becquerel Institut de Cancérologie de l'Ouest

About

Marianne Leheurteur is an author at Centre Jean Perrin specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	2.1K
2	Health Sciences	3	3	91
3	Public Health	2	2	454
4	Engineering	1	1	82
5	Biostatistics	1	1	274

Marianne Leheurteur

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Thomas Bachelot, Gilles Romieu, Mario Campone, The Lancet Oncology Breast OncologyBrain MetastasesMedicineCancer ManagementPharmacology	2012	733
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer Mathilde Bayet‐Robert, Fabrice Kwiatowski, Marianne Leheurteur, Cancer Biology & Therapy	2010	386
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Élisa Gobbini, Monia Ezzalfani, Véronique Dièras, European Journal of Cancer Prognostic EvaluationBreast OncologyMedicineTime TrendsEpidemiology Of Cancer	2018	274
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort Amélie Darlix, G. Louvel, Julien Fraisse, British Journal of Cancer	2019	206
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016 Élise Deluche, Alison Antoine, Thomas Bachelot, European Journal of Cancer Metastatic Breast CancerBreast OncologyCancer EpidemiologyMedicineEpidemiology Of Cancer	2020	180
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial Benoît You, Patrick Robelin, Michel Tod, Clinical Cancer Research	2020	121
Kinetics, prognostic and predictive values of <i>ESR1</i> circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor Florian Clatot, Anne Perdrix, Laetitia Augusto, Oncotarget	2016	95
Short report: Monitoring <scp><i>ESR</i></scp><i>1</i> mutations by circulating tumor <scp>DNA</scp> in aromatase inhibitor resistant metastatic breast cancer David Sefrioui, Anne Perdrix, Nasrin Sarafan‐Vasseur, International Journal of Cancer Breast OncologyEngineeringClear Esr1 MutationPathologyEsr1 Mutations	2015	82

Page 1